Technology Transfer

Life Sciences

Dr Iain Thomas - Head of Life Sciences

Iain is Head of Life Sciences at Cambridge Enterprise.

Cambridge Enterprise’s Life Sciences product portfolio includes alemtuzumab (Sanofi), breast cancer markers (Brevagen) and mouse touch screen chambers (Campden Instruments). Recent spin-outs include Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor and Phoremost. Recent transactions include licences in fields as diverse as therapeutics, diagnostics, biofuels, IVF and epigenetics and the sale of XO1 to Johnson & Johnson. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the SBC.

Dr Amanda Wooding - Deputy Head of Life Sciences

Amanda joined the team in 2009 and has managed project portfolios and negotiated complex licenses across a wide range of life science technology areas. Recent activities have involved licensing a portfolio of technology assets in the biomaterials field, the establishment of a new genomics related spin-out company Inivata Ltd and raising funding for University initiatives in the translational research space. Amanda sits as the CE Investment Director on the board of Sphere Fluidics Ltd.

Before joining Cambridge Enterprise, she gained over 10 years of experience in technology commercialisation from roles within The Wellcome Trust and at Acambis. As the UK-based Director of Business Development at Acambis, she was responsible for in- and out-licensing, most notably securing a Phase III out-licensing deal with Sanofi Pasteur. While at the Wellcome Trust, she served as the Wellcome Trust observer to the Board for three start-up biotechnology companies. Amanda has a PhD in molecular endocrinology from the University of Cambridge and enjoyed post-doctoral research positions both at Cambridge and in industry.

Dr Rachel Atfield - Technology Manager

Rachel joined Cambridge Enterprise in 2006 and has experience of commercialising technology from a variety of sectors including diagnostics, medical devices and software.

She has completed a variety of deals including a licence with a large US medical company for a technology to revolutionise diabetes treatment and has particular experience of working in the field of psychiatry and cognition where she has negotiated licences with multiple partners including a US based molecular diagnostics company. Before joining Cambridge Enterprise, Rachel worked as a Patent Analyst at Thomson Scientific, specializing in patent searching and patent-based intelligence for the biotech and pharmaceutical industries. Rachel has a BSc in Biology from Imperial College London and a PhD in Virology from the University of Cambridge.

Dr Emma Barker - Senior Technology Associate

Emma has experience in identifying, managing, developing and commercialising a variety of life sciences IP.

She led the licence discussions with GSK for the GSK Drug Discovery Partnership with Academia project at Cambridge, and manages Cambridge’s involvement in the Eli Lilly Open Innovation Drug Discovery Program. Emma also works with academics to secure translational funding to further develop IP – this has led to several multi-£million awards including several Seeding Drug Discovery Awards from the Wellcome Trust and an MRCT Centre for Therapeutics Discovery Programme.

She also supports projects as part of the University of Cambridge – GSK Open Innovation Drug Discovery Initiative at the Stevenage BioCatalyst. Before joining Cambridge Enterprise, Emma enjoyed ten years in the pharma/biotech sector, including managing BioFocus GPCR small molecule drug discovery and optimisation programmes in a variety of therapeutic areas, and management of the IP portfolio to deliver data packages for subsequent partnering. Emma has a PhD in Organic Chemistry from the University of Leicester.

Dr Laura Donnelly - Technology Manager

Laura joined Cambridge Enterprise in 2011 and has experience in identifying, managing, developing and commercialising a range of life sciences IP.

She has particular experience of working in the fields of stem cell research, medical devices, biomarkers and microfluidic technologies and has worked on a variety of deals including a licence with a large US medical company for a technology to revolutionise diabetes treatment. Laura also supports projects as part of the University of Cambridge – GSK Open Innovation Drug Discovery Initiative at the Stevenage Bioscience Catalyst. As part of her role at Cambridge Enterprise, Laura spent 5 months on secondment as a business development manager at one of Cambridge Enterprise’s spin-out companies, Cambridge Epigenetix.

Before joining Cambridge Enterprise, Laura worked as a postdoctoral researcher at the University of Manchester, studying the regulation of cardiac function and disease by cell signalling pathways. Laura obtained a PhD in Biochemistry from the University of Manchester and a BSc in Biochemistry from the University of York.

Dr Helen Young - Senior Associate

Helen joined Cambridge Enterprise in 2013. She brings over 15 years' industrial experience, having worked for various SMEs in the biotech sector within the Cambridge region.

She has held senior positions in the areas of process development, manufacturing and formulation development for vaccines and biotherapeutics, and has additional experience within the field of clinical biomarkers through employment with Merck Serono. She has a PhD in Biochemistry from Manchester University.

Dr Dafne Chirivino - Senior BRC Intellectual Property Associate

Dafne joined Cambridge Enterprise in January 2017. Dafne has several years of industrial experience, having worked for various major International Pharmaceutical and Medtech Companies.

She has held senior positions in the area of Market Intelligence and Business Strategy, and worked as an external consultant for different companies such as Roche, Novartis, Bayer, Merck Serono, Alexion, Takeda, Nestlé and Medtronic.

Dafne works with Cambridge University Hospitals (CUH) Department of Research and Development and Cambridge Enterprise to identify and commercialise intellectual property originating from research carried out within the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.

Before joining Cambridge Enterprise, Dafne worked as a Market Intelligence Analyst at Debiopharm International and as a Project Manager at Alcimed. Dafne obtained a PhD in Biology from the Institute Curie (Paris, France) and the University Paris XI (Paris, France) as well as a Master Degree in Molecular Biology from the University “La Sapienza” of Rome (Italy).

Dr Vibha Tamboli - Technology Associate

Vibha joined Cambridge Enterprise as a Technology Associate in January 2017. She has a Master’s degree in Biotechnology from the Northwestern University and completed her PhD in Pharmacy and Pharmaceutical Sciences at Cardiff University in May 2017.

Vibha focused on generation of synthetic receptors for detection of prostate cancer biomarkers during her PhD. She worked on development of a synthetic receptor-based biosensor for detection of prostate specific antigen (PSA). Prior to joining Cambridge Enterprise, Vibha interned at the Technology Transfer Office at Cardiff University.

Dr Geoff Elliott - Technology Associate

Geoff joined Cambridge Enterprise in 2016, following an extensive postdoctoral career in life sciences research, management, and commercialisation in academia and industry, both in the UK and USA, and the subsequent attainment of a Graduate Diploma in Law in 2015.

Prior to joining Cambridge Enterprise, Geoff most recently worked as an independent research consultant within commercial genetic test development, and prior to this was a Senior Molecular Microbiologist at the James Hutton Institute, working in industrial and environmental pathogen detection methodologies, microbial profiling and bacterial epidemiology.

Dr David Cavalla - Senior Consultant

David has 30 years' experience in various senior scientific and commercial roles within the pharmaceutical industry. He is currently involved with a number of biotech companies at Board level. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre.

He is author of Modern Strategy for Pharmaceutical R&D – Towards the Virtual Research Centre, and Off-Label Prescribing: Justifying Unapproved Medicine. He is one of the first advocates of drug re-purposing, and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages.

David frequently contributes articles on pharmaceutical strategy and is on the editorial board of Drug Discovery Today. Formerly he was Chairman of the Society for Medicines Research. He obtained a first degree and PhD at the University of Cambridge and spent two years as a visiting Fellow at the NIMH, Washington, DC. He is author/inventor of more than 70 published papers and patents.

Physical Sciences

Dr Malcolm Grimshaw - Head of Physical Sciences

Malcolm joined Cambridge Enterprise in the summer of 2002 and is now Head of the Physical Sciences team, working with technologies across the whole range of physical sciences.

His scientific background is in physics, with a first degree from the University of Oxford and a PhD from the University of Nottingham. Malcolm spent three years as a researcher in Grenoble before moving into the scientific equipment industry. He enjoyed 18 years in the cryogenic and vacuum instrumentation industries, initially as an engineer before moving into sales, marketing and new product development.

Dr Margaret Wilkinson - Technology Manager

Maggie focuses on the commercialisation of technologies from engineering and physical sciences (including software), and joined Cambridge Enterprise in 2001.

Prior to this, she worked for a multinational oil company, initially developing new oil and fuel products for the automotive sector, and more recently in the analysis of environmental and economic data to help formulate business strategy. Maggie holds a degree in Natural Sciences and a PhD in Solid State Physics from the University of Cambridge. Maggie has experience in the commercialisation of technology across the range of physical sciences and has worked with the spin-outs Enval, Metalysis and Camfridge.

Dr Gillian Davis - Technology Manager

Gillian joined Cambridge Enterprise in 2009. She holds a BA in Natural Sciences from Oxford University and a doctorate in laser applications.

Having spent ten years as an R&D engineer, she moved into hi-tech business development in 1997, obtaining an MBA with the Open University in 1998. After running the subsidiary of the US company Noise Cancellation Technologies for ten years, she took up the post of Commercial Director at Dolomite Microfluidics in 2007.

Dr Charlanne Ward - Technology Manager

Charlanne holds a PhD in Optical Electronics and a degree in Electrical and Information Sciences from the University of Cambridge, and is a Chartered Engineer.

Charlanne spent 11 years working at a global telecommunication equipment manufacturer, including seven years in R&D followed by four years as a portfolio manager responsible for the commercialisation and management of the company’s professional services portfolio in Europe, the Middle East and Africa. Prior to joining Cambridge Enterprise, Charlanne was an independent consultant in the areas of technology and business strategy, with a particular interest in electronics and low carbon solutions.

Julian Peck - Technology Manager

Julian has been with Cambridge Enterprise since 2012, working across physical sciences and technology, including software.

He is a Cambridge graduate from the Institute for Manufacturing and a Chartered Mechanical Engineer, with considerable industrial and commercial experience, especially in automotive, consumer products and technology. He has worked in corporate finance and is a serial entrepreneur, and has now been patenting inventions and commercialising innovations for over 20 years.

Dr Olivia Nicoletti - Senior Associate

Olivia joined Cambridge Enterprise as a Technology Associate at the beginning of 2015. She holds a degree in Physics from the University of Milan (Universitá Statale di Milano) and a PhD in Materials Science and Metallurgy from the University of Cambridge, where she was also a postdoc for a year.

She specialised in nanotechnology, with particular focus on optical physics at the nanoscale, working in fields such as nanophotonics and plasmonics. Prior to joining Cambridge Enterprise, Olivia was involved in scientific publishing, working as an associate editor at Nature Materials within the London office of Nature Publishing Group.

Ben Ting - Technology Associate

Ben joined Cambridge Enterprise in mid-2016.

He is a Chartered Mechanical Engineer and holds a MPhil in Industrial Systems, Manufacture and Management from the Institute for Manufacturing (IfM), University of Cambridge and a Bachelor’s degree in Mechatronics Engineering from the University of New South Wales, Australia.

Before joining Cambridge Enterprise, Ben worked in various engineering capacities in vehicle development and lean manufacturing in the defence sector.  He also has experience in automotive and buildings engineering.

+44 (0)1223 765793 Ben.Ting@enterprise.cam.ac.uk Print

Dr Jennie Flint - Technology Associate

Jennie joined Cambridge Enterprise as a Technology Associate in mid-2016. She has a Masters degree in Chemistry from the University of Sussex and a PhD in Chemistry from the University of Cambridge.

Jennie focused on quantum dot synthesis for single molecule fluorescence applications for her Masters. This led her to study the aggregation of amyloid beta 42 (a peptide implicated in Alzheimer’s Disease) using single molecule fluorescence techniques and microfluidics during her PhD. Prior to joining Cambridge Enterprise, Jennie worked as a Product Specialist for a major biotechnology company, with an emphasis on global regulatory compliance.

Elisabeth Barker - Technology Transfer, PA

Elisabeth Barker joined Cambridge Enterprise in 2014 as PA to the Technology Transfer team.

Liz has 15 years of executive assistant experience within investment banking in the City of London. Before starting work with Cambridge Enterprise, Liz worked at Cambridge & Peterborough NHS Foundation Trust in Mental Health for the Head of Professional Nursing and the Trust Lead for Allied Health Professions

Image: University spin-out Sphere Fluidics’ fusion biochip, which was licensed with the help of Cambridge Enterprise’s Technology Transfer teams.